Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$38.23 USD

38.23
1,387,305

-0.39 (-1.01%)

Updated Aug 8, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Sarepta's Casimersen NDA Gets Priority Review From FDA

by Zacks Equity Research

Sarepta (SRPT) is seeking accelerated approval for exon 45 amenable DMD candidate, casimersen. Amondys 45 is likely to be the brand name for the candidate.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals

by Kinjel Shah

J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma

Zacks Equity Research

Regeneron Gains on Coronavirus Treatment Development Efforts

by Zacks Equity Research

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.

Zacks Equity Research

Regeneron, Roche to Distribute Antibody Cocktail for Coronavirus

by Zacks Equity Research

Regeneron (REGN) teams up with Roche to develop and distribute REGN-COV2, its experimental dual antibody cocktail for the prevention and treatment of COVID-19.

Zacks Equity Research

Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug

by Zacks Equity Research

Gilead (GILD) suffers a setback as the FDA issues a CRL for its rheumatoid arthritis drug.

Zacks Equity Research

AstraZeneca's Imfinzi Gets Priority Tag for 4-Week Dosing

by Zacks Equity Research

The FDA grants priority review to AstraZeneca's (AZN) sBLA seeking approval of Imfinzi for a four-week fixed-dose regimen for its approved indications in bladder cancer and non-small cell lung cancer.

Zacks Equity Research

PTC Therapeutics' Application for SMA Drug Accepted by EU

by Zacks Equity Research

PTC Therapeutics??? (PTCT) MAA for Evrysdi is accepted by the European Medicines Agency for the treatment of spinal muscular atrophy.

Zacks Equity Research

Bristol Myers & Dragonfly Team Up for Immunotherapy Program

by Zacks Equity Research

Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.

Zacks Equity Research

Gilead Expands Collaboration With Tango for Cancer Therapies

by Zacks Equity Research

Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.

Zacks Equity Research

Roche Gets FDA Nod for Nervous System Disorder Drug Enspryng

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for NMOSD drug under the brand name, Enspryng.

Zacks Equity Research

Sanofi to Buy Immunology Firm Principia Biopharma for $3.7B

by Zacks Equity Research

Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates

by Kinjel Shah

Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).

Zacks Equity Research

Roche's Xolair sBLA for Self Administration Accepted by FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) sBLA for a new self-administration option for Xolair across all approved U.S. indications.

Zacks Equity Research

AbbVie Outperforms Large-Cap Pharma Industry Year to Date

by Zacks Equity Research

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.

Zacks Equity Research

Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.

Kinjel Shah headshot

Alzheimer's in Focus as Biogen's Aducanumab Gets Priority Tag

by Kinjel Shah

If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Zacks Equity Research

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

Zacks Equity Research

Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the second quarter.

Zacks Equity Research

Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes

by Zacks Equity Research

Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.

Zacks Equity Research

Bayer (BAYRY) Q2 Earnings & Sales Fall Y/Y, Guidance Tweaked

by Zacks Equity Research

Bayer's (BAYRY) earnings and sales fall year over year in the second quarter of 2020.

Zacks Equity Research

Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.

Zacks Equity Research

ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down

by Zacks Equity Research

ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.

Zacks Equity Research

AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Zacks Equity Research

Merck (MRK) Beats on Q2 Earnings, Misses Sales, Ups View

by Zacks Equity Research

Merck (MRK) increases earnings and sales guidance for the year, which pushes shares up in pre-market trading.

Zacks Equity Research

Gilead (GILD) Misses on Q2 Earnings & Sales, Ups '20 Guidance

by Zacks Equity Research

Gilead (GILD) reports weaker-than-expected results for the second quarter but ups annual guidance.